Adagio (insulin) / Aerami Therap, Hikma - LARVOL DELTA

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (clinicaltrials.gov) - P3 | N=352 | Recruiting | Sponsor: Bristol-Myers Squibb | N=103 ➔ 352

Enrollment change • Trial initiation date • Alzheimer's Disease • CNS Disorders • Aβ42 • CSF Aβ42 • p-tau181

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (clinicaltrials.gov) - P3 | N=352 | Recruiting | Sponsor: Bristol-Myers Squibb

Trial initiation date • Alzheimer's Disease • CNS Disorders • p-tau181

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Bristol-Myers Squibb | N=193 ➔ 600

Enrollment change • Alzheimer's Disease • CNS Disorders

VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study (clinicaltrials.gov) - P=N/A | N=130 | Not yet recruiting | Sponsor: Adagio Medical | Trial completion date: Jun 2026 ➔ Sep 2027 | Trial primary completion date: Jun 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Cardiovascular • Ventricular Tachycardia

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (clinicaltrials.gov) - P3 | N=352 | Recruiting | Sponsor: Bristol-Myers Squibb

Trial initiation date • Alzheimer's Disease • CNS Disorders • Aβ42 • CSF Aβ42 • p-tau181

CN012-0024: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for thenTreatment of Agitation Associated with Alzheimers Disease. (clinicaltrialsregister.eu) - P2/3 | N=90 | Recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

New P2/3 trial • Alzheimer's Disease • CNS Disorders • Aβ42 • CSF Aβ42 • p-tau181

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (clinicaltrials.gov) - P3 | N=352 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) (clinicaltrials.gov) - P3 | N=352 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (clinicaltrials.gov) - P3 | N=352 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P3 trial • Alzheimer's Disease • CNS Disorders

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) (clinicaltrials.gov) - P3 | N=352 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P3 trial • Alzheimer's Disease • CNS Disorders

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Nov 2028 ➔ Jul 2029 | Trial primary completion date: Nov 2028 ➔ Jun 2029

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P3 trial • Alzheimer's Disease • CNS Disorders

Dual tracer guided laparoscopic gastrectomy for gastric cancer (DANCE-02): a randomized prospective clinical trial (IGCC 2025) - P=N/A | "Dual tracer strategy of laparoscopic gastrectomy leads to more LNs, shorter operation time, less blood lost and accelerated postoperative recovery in patients with gastric cancer."

Clinical • Gastric Cancer • Oncology • Solid Tumor

Type 2 Diabetes Mellitus in Saudi Arabia: Prevalence, Risk Factors, and Management Strategies: A Review. (PubMed, Endocr Metab Immune Disord Drug Targets) - "Obesity is the main risk factor for type 2 diabetes mellitus (T2DM), which involves insulin resistance and β-cell dysfunction. This review examines the impact of T2DM in KSA, its risk factors and complications, and the role of Dapagliflozin in its management. It also provides expert opinions on the current situation of T2DM in KSA."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Florida | Active, not recruiting ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: University of Florida | Recruiting ➔ Active, not recruiting

Enrollment closed • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Once-weekly insulin icodec as novel treatment for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. (PubMed, Diabetes Res Clin Pract) - "This study suggests similar efficacy and safety between insulin icodec and regular basal insulin. Further clinical trials are still needed to confirm the results of our study."

Clinical • Journal • Retrospective data • Review • Diabetes • Endocrine Disorders • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: University of Florida | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Paternal zinc deficiency alters offspring metabolic status in Drosophila melanogaster. (PubMed, J Trace Elem Med Biol) - "These findings underscore the link between zinc status and various physiological and molecular processes, revealing both immediate and intergenerational impacts on metabolic, antioxidant, and inflammatory pathways and providing valuable insights on the implications of paternal zinc deficiency in Drosophila melanogaster."

Journal • Metabolic Disorders

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Florida | Initiation date: Jun 2024 ➔ Oct 2024

Trial initiation date • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor

VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study (clinicaltrials.gov) - P=N/A | N=130 | Not yet recruiting | Sponsor: Adagio Medical

New trial • Cardiovascular • Ventricular Tachycardia

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University of Florida

New P1 trial • Brain Cancer • CNS Tumor • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Subserosal Indocyanine Green Plus Submucosal Carbon Nanoparticle Navigated Laparoscopic Gastrectomy (DANCE-01): a Cohort Study. (PubMed, J Gastrointest Surg) - "We propose a novel, feasible and safe tracing strategy for laparoscopic gastrectomy."

Journal

[VIRTUAL] ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (SGO 2021) - No abstract available

Clinical • P2b data • Endometrial Serous Adenocarcinoma • Oncology • Uterine Cancer